AUNA vs. THC: Which Ambulatory Care Stock Is the Smarter Bet Now?

Auna completed an $825M debt refinancing, improved cash position by 42% and reported leverage of 3.6x, while focusing on Peru growth, Mexico recovery and Colombia risk-sharing models. Tenet generated $21.3B revenue (+14% YoY), adjusted EBITDA margin of 21.4% (+200bps), USPI same-facility revenue +7.5% and free cash flow of $2.53B with leverage at 2.25x; management expects a $250M 2026 EBITDA headwind from expiring tax credits. YTD price performance: AUNA +7.4%, THC -5.4%; valuation: AUNA forward 5yr P/S 0.31x (vs median 0.41x), THC P/S 0.75x. Zacks ranks AUNA #1 (Strong Buy) and THC #3 (Hold).

Analysis

The ambulatory migration is creating an asymmetric payoff: asset-light ASC portfolios and vertically integrated outpatient platforms capture incremental margin per case faster than legacy hospitals because they avoid inpatient fixed-cost absorption and can scale pre-negotiated physician economics. The second-order winners are not only ASC owners but their equipment and implant suppliers (orthopedics, endoscopy), and software/automation vendors that reduce per-case labor intensity — these suppliers will see order visibility improve as ASCs expand specialty mixes.

Key catalysts that will re-rate issuers are execution on capacity buildouts (groundbreaking, licensing, facility openings), demonstrable FCF conversion versus headline EBITDA, and concrete payer-contract wins for higher-margin payor segments; conversely, near-term reversals can come from LATAM FX shocks, abrupt reimbursement reform, or an elective-surgery slowdown in the US. Time horizons split: operational inflection (volume/payer mix) plays out over 2–4 quarters, while capital-structure and regulatory outcomes take 6–18 months to fully manifest.

The market appears to underprice operational optionality in vertically integrated LATAM platforms that can re-segment patients into out-of-pocket and risk-sharing pools — this creates optionality for improved EBITDA per bed as private-insured penetration increases. Meanwhile, large US hospital operators may be under-discounted for downside if the outpatient shift accelerates faster than their capital redeployment plans; that asymmetry supports selective long-LATAM / hedge-US pairings rather than outright long-US-hospital exposure alone.

Key Decisions for Investors

• Long AUNA (AUNA) — size 2–3% of fund: buy a 12-month call spread ~25% out-of-the-money (buy nearer-term call, sell higher strike) to express upside from Mexico outpatient recovery and LATAM oncology monetization. Reward: asymmetric upside if FCF conversion and payer wins are confirmed in next 2 quarters; Risk: LATAM FX or a regulatory shock could compress valuation — max loss = premium paid (~small % NAV).
• Pair trade — long AUNA 2.5% / short Tenet (THC) 1.5% over 6–12 months: this isolates regional/regulatory and outpatient-mix execution. Thesis: AUNA re-rate on operational optionality while THC is more exposed to inpatient cyclical risk and expiration of favorable tax mechanics; Risk: faster-than-expected ASC migration in the US benefits THC and could invert the trade.
• Protective hedge on Tenet (THC) — size 1% of fund: purchase 9–12 month puts ~15% out-of-the-money to guard against an elective-volume shock or unexpected deterioration in hospital payer mix. Reward: limited premium protects portfolio if headline volumes fall; Risk: premium decay if US volumes remain steady.
• Event conditional allocation: add to AUNA on two triggers within 120 days — (1) public confirmation of Torre Trecca construction milestone or material PPP payment schedule and (2) quarter-over-quarter improvement in private-pay mix in Mexico. On either trigger increase to 4–5% position; if both fail and LATAM FX weakens materially, reduce to zero.